Drug Database
Back to search

Poland· PL-100349082

Synjardy

A metformin and empagliflozin product containing empagliflozinum + metformini hydrochloridum, registered in Poland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.

ATC A10BD20

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSynjardyATCA10BD20REGISTER NO.PL-100349082PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about empagliflozinum + metformini hydrochloridumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Metformin and empagliflozin is registered in 13 of 19 countries.

Countries holding a registration under ATC A10BD20 (metformin and empagliflozin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search metformin and empagliflozin products by name

Metformin and empagliflozin · ATC A10BD20

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Empagliflozinum + Metformini hydrochloridum
Manufacturer
Boehringer Ingelheim International GmbH
Country
Poland (PL)
ATC code
A10BD20
ATC class
Metformin and empagliflozin
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991421427

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Metformin and empagliflozin in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All metformin and empagliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Empagliflozin/Metformin Hcs
  • Belgium · Empagliflozine/Metformine Hcl Hcs
  • Bulgaria · Empafel Met 5 Mg/850 Mg, Емпафел Мет
  • Cyprus · Empagliflozin/Metformin Tad
  • Czechia · Mempoglyn
  • Denmark · Empagliflozin/Metformin Krka
  • Estonia · Mempoglyn
  • Spain · Empagliflozina/Metformina Krka
  • Greece · Mempoglyn
  • Croatia · Mempoglyn
  • Hungary · Mempoglyn
  • Ireland · Empagliflozin/Metformin Krka
  • Iceland · Appref, Empagliflozin-Metformin Adalvo
  • Liechtenstein · Synjardy
  • Lithuania · Mempoglyn
  • Luxembourg · Empagliflozin/Metformin Hcl Ab
  • Latvia · Mempoglyn
  • Malta · Appref, Empagliflozin-Metformin Adalvo
  • Netherlands · Appref, Empagliflozine/Metformine Hcl Hcs
  • Norway · Empagliflozin/Metformin Krka, Synjardy
  • Portugal · Empagliflozina + Metformina Aurobindo, Empagliflozina + Metformina Generis
  • Romania · Mempoglyn
  • Slovenia · Emameten, Empagliflozin/Metformin Krka

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a47e89e1-d752-4f7f-9436-04d1eaa694f8
GET /v1/drugs/a47e89e1-d752-4f7f-9436-04d1eaa694f8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "5 mg + 1000 mg",
  "packaging": "Rp ¦ Eu/1/15/1003/010 ¦ 109582\n10 tabl.\n05909991421427 ¦ Rp ¦ EU/1/15/1003/014 ¦ 109583\n60 tabl.\nRp ¦ EU/1/15/1003/012 ¦ 109584\n30 tabl.\nRp ¦ EU/1/15/1003/013 ¦ 109585\n56 tabl.\nRp ¦ EU/1/15/1003/011 ¦ 109586\n14 tabl.\nRp ¦ EU/1/15/1003/015 ¦ 109587\n100 tabl.\nRp ¦ EU/1/15/1003/016 ¦ 109588\n120 tabl.\nRp ¦ EU/1/15/1003/017 ¦ 109589\n180 tabl.\nRp ¦ EU/1/15/1003/018 ¦ 109590\n200 tabl.\nRp ¦ EU/1/15/1003/038 ¦ 122905\n90 tabl.",
  "substance": "Empagliflozinum 5 mg + Metformini hydrochloridum 1000 mg",
  "common_name": "Empagliflozinum + Metformini hydrochloridum",
  "pl_product_id": "100349082",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about metformin and empagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console